专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US11111225B2 Calixarene compound and curable composition 有权
公开(公告)号：US11111225B2
公开(公告)日：2021-09-07
申请号：US16463037
申请日：2017-11-16
申请人： DIC Corporation
发明人： Shinya Yamamoto , Masanori Miyamoto , Tomoyuki Imada
IPC分类号： C07D303/23 , C07C43/225 , C07C49/83 , C07C69/653 , C07C69/712 , C07C323/16 , C07D305/06 , C08L33/10 , C07F9/38 , C07C43/23 , C07C327/06 , C07F9/12 , C07C323/12 , C07C59/66 , C07F9/09 , C07F7/04 , B29C33/60 , C07D303/34 , C07F1/00 , H01L21/027 , C07D201/00 , C07D209/48
摘要： A compound useful as a release agent, and a release agent, a curable composition, and a nanoimprint lithography resin material each containing the compound are provided. More specifically, a calixarene compound with a molecular structure represented by the following structural formula (1) and a composition containing the calixarene compound are provided. wherein R1 denotes a structural moiety with a perfluoroalkyl group, R2 denotes a hydrogen atom, a polar group, a polymerizable group, or a structural moiety with a polar group or a polymerizable group, R3 denotes a hydrogen atom, an aliphatic hydrocarbon group that may have a substituent, or an aryl group that may have a substituent, n denotes an integer in the range of 2 to 10, and * denotes a bonding point with an aromatic ring.

2. 发明授权

US10668079B2 Composition composed of ceftriaxone sodium and sulbactum sodium 审中-公开
公开(公告)号：US10668079B2
公开(公告)日：2020-06-02
申请号：US16093685
申请日：2016-11-02
申请人： XIANGBEI WELMAN PHARMACEUTICAL CO., LTD. , GUANGZHOU WELMAN NEW DRUG R&D CO., LTD. , NANJING KANGFUSHUN PHARMACEUTICAL CO., LTD.
发明人： Mingjie Sun
IPC分类号： A61K31/546 , A61P31/04 , A61K31/43 , A61K9/00 , A61K9/19 , A61K9/14 , C07D201/00 , A61K9/08
摘要： The present disclosure provides a composition consisting of ceftriaxone sodium and sulbactam sodium, a pharmaceutical formulation comprising the same and the application thereof. The composition is characterized by having an X-ray powder diffraction pattern with peaks at specific angles. The pharmaceutical formulation according to the present disclosure have better antibacterial activity and stability compared with known compositions, and are thus very suitable for the treatment of bacterial infections, especially for the treatment of refractory urogenital system infections caused by Neisseria gonorrhoeae which has drug-resistance to a variety of antibiotics (β-lactams, tetracyclines, macrolides, fluoroquinolones and aminoglycosides).

3. 发明申请

US20020158352A1 High refractive index triazine monomer 失效
$High refractive index triazine monomer$
标题翻译：高折射率三嗪单体
公开(公告)号：US20020158352A1
公开(公告)日：2002-10-31
申请号：US09925479
申请日：2001-08-10
发明人： Eun Kyoung Kim
IPC分类号： C07D201/00
CPC分类号： C07D251/10 , C07D251/46
摘要： The present invention relates to a triazine type monomer, and more particularly, to a 1,3,5-triazine type monomer characterized by having at least one amine group and at least two sulfur atoms, which can be used in manufacturing transparent optical resins having excellent refractive index, surface hardness and absorbance as well as an improved workability and the ability to control a wide range of refractive index according to the change in composition by the monomer itself at room temperature or by polymerizing the monomer with a comonomer in the presence of an organic solvent or an initiator.
摘要翻译：本发明涉及三嗪型单体，更具体地说，涉及一种具有至少一个胺基和至少两个硫原子的1,3,5-三嗪型单体，其可用于制造具有优异的折射率，表面硬度和吸光度以及改进的可加工性以及根据单体本身在室温下的组成变化来控制宽范围的折射率的能力，或通过在共聚单体存在下将共聚单体聚合有机溶剂或引发剂。

4. 发明申请

US20210040148A1 THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA 有权
公开(公告)号：US20210040148A1
公开(公告)日：2021-02-11
申请号：US17077859
申请日：2020-10-22
申请人： Mayo Foundation for Medical Education and Research , Regents of the University of Minnesota
发明人： Michael P. Fautsch , Peter Dosa , Michael A. Walters , Gunda I. Georg
IPC分类号： C07K5/062 , C07D405/04 , C07D405/12 , C07D285/24 , A61K31/549 , A61K31/454 , A61K31/4025 , A61K9/00 , A61K31/675 , A61K31/4439 , C07D201/00 , A61K31/353 , C07D311/20 , C07D311/70 , C07D405/14 , C07F9/6547 , C07F9/6558
摘要： The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and/or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a KATP channel to reduce an intraocular pressure.

5. 发明授权

US08217182B2 Process for producing cyclic N-hydroxy imide compounds 有权
标题翻译：环状N-羟基酰亚胺化合物的制备方法
公开(公告)号：US08217182B2
公开(公告)日：2012-07-10
申请号：US12510393
申请日：2009-07-28
申请人： Yasuteru Kajikawa
发明人： Yasuteru Kajikawa
IPC分类号： A61K31/395 , A61K31/35 , C07D201/00 , C07D307/02 , C07D309/02
CPC分类号： C07D309/32
摘要： A cyclic polycarboxylic acid anhydride, a polycarboxylic acid, or a mixture of them is allowed to react with hydroxylamine or a salt thereof in an organic solvent under dewatering conditions to yield a corresponding cyclic N-hydroxyimide compound. The cyclic polycarboxylic acid anhydride can be, for example, succinic anhydride or glutaric anhydride. The polycarboxylic acid can be, for example, succinic acid, glutaric acid, or adipic acid. In this process, the reaction is preferably carried out using an organic solvent capable of undergoing azeotropy with water as all or part of a reaction solvent while removing water from the reaction system by azeotropy with the organic solvent. This process produces a cyclic N-hydroxyimide compound in a good yield from any of a cyclic polycarboxylic acid anhydride and a polycarboxylic acid.
摘要翻译：在脱水条件下，使环状多元羧酸酐，多元羧酸或它们的混合物与羟胺或其盐在有机溶剂中反应，得到相应的环状N-羟基酰亚胺化合物。环状多元羧酸酐可以是例如琥珀酸酐或戊二酸酐。多元羧酸可以是例如琥珀酸，戊二酸或己二酸。在该方法中，优选使用能够与水共沸的有机溶剂作为全部或部分反应溶剂进行反应，同时通过与有机溶剂共沸除去反应体系中的水分。该方法以环状多元羧酸酐和多元羧酸中的任何一种产生良好的收率的环状N-羟基酰亚胺化合物。

6. 发明申请

US20110160370A1 ACID ENDCAPPED CAPROLACTONE OR VALEROLACTONE DISPERSING AGENTS 有权
标题翻译： ACID ENDCAPPED CAPROLACTONE或VALEROLACTONE DISPERSING AGENTS
公开(公告)号：US20110160370A1
公开(公告)日：2011-06-30
申请号：US13062323
申请日：2009-08-13
申请人： Patrick J. Sunderland , Dean Thetford , Thomas Forder
发明人： Patrick J. Sunderland , Dean Thetford , Thomas Forder
IPC分类号： C08K5/19 , C07C61/08 , C07D201/00 , C07C67/02 , C08K5/09 , C08K5/17
CPC分类号： C08K5/101 , B01F17/0021 , C08G63/08 , C08L67/04
摘要： The invention relates to a composition containing a particulate solid, a plastic material (such as a thermoplastic polymer) and a compound capable of having dispersant properties. The compound may be obtained/obtainable by reacting a fatty acid with either (i) a hydroxy-C4-5-alkylene carboxylic acid, or (ii) a lactone. The invention further relates to novel compounds, and the use of the compound as a dispersant.
摘要翻译：本发明涉及包含微粒固体，塑料（例如热塑性聚合物）和能够具有分散性的化合物的组合物。该化合物可以通过使脂肪酸与（i）羟基-C4-5亚烷基羧酸或（ii）内酯反应获得/获得。本发明还涉及新化合物，以及该化合物作为分散剂的用途。

7. 发明申请

US20050119258A1 A1 adenosine receptor antagonists 失效
标题翻译： A1腺苷受体拮抗剂
公开(公告)号：US20050119258A1
公开(公告)日：2005-06-02
申请号：US10780296
申请日：2004-02-17
申请人： Constance Wilson , John Partridge
发明人： Constance Wilson , John Partridge
IPC分类号： A61K31/522 , A61K31/5377 , A61K31/541 , C07D20060101 , C07D201/00 , C07D473/04
CPC分类号： C07D473/04
摘要： Compounds of the general formula (I) are described: wherein A is a 5- or 6-membered aromatic or heteroaromatic ring. Compositions comprising such compounds and methods of use thereof are also described.
摘要翻译：描述通式（I）的化合物：其中A是5-或6-元芳族或杂芳族环。还描述了包含这些化合物的组合物及其使用方法。

8. 发明申请

US20030100042A1 NOVEL ANTIMICROBIAL ACTIVITY OF GEMFIBROZIL 失效
标题翻译： GEMFIBROZIL的新型抗微生物活性
公开(公告)号：US20030100042A1
公开(公告)日：2003-05-29
申请号：US08608712
申请日：1996-02-29
发明人： CHRISTINA KABBASH , HOWARD A. SHUMAN , SAMUEL C. SILVERSTEIN , PHYLLIS DELLA-LATTA
IPC分类号： C12N009/00 , C12Q001/18 , C12Q001/02 , C12Q001/00 , C12Q001/26 , C07D201/00
CPC分类号： A61K31/192 , Y02A50/478 , Y02A50/481
摘要： The present invention provides for a method for inhibiting growth of a bacterium which consists essentially of contacting the bacterium with a compound having the structure: 1 wherein each of R1, R2, R3, R4, R5 and R6 may be independently H, F, Cl, Br, I, nullOH, nullOR7, nullCN, nullCOR7, nullSR7, nullN(R7)2, nullNR7COR8, nullNO2, null(CH2)pOR7, null(CH2)pX(R7)2, null(CH2)pXR7COR8, a straight chain or branched, substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, thioalkyl, methylene thioalkyl, acyl, phenyl, substituted phenyl, or heteroaryl; wherein a linkage to the benzene ring may alternatively be nullNnull, nullSnull, nullOnull or nullCnull; wherein R7 or R8 may be independently H, F, Cl, Br, I, nullOH, nullCN, nullCOH, nullSH2, nullNH2, nullNHCOOH, null(CH2)pOH, null(CH2)pX(CH2), null(CH2)pXCOH, a straight chain or branched, substituted or unsubstituted C1-C10 alkyl, thioalkyl, methylene thioalkyl, acyl, phenyl, substituted phenyl, or heteroaryl; wherein A may be nullN2null, nullNHnull, nullCnullCnullCH2null, nullCnullCnullC2HOHnull, nullCnullCnullCH2null, nullCH2nullCH2nullOnull, nullCH2nullCH2nullCH2nullOnull, nullSnull, nullS(nullO)2null, nullCnullOnull, nullCnullOnullOnull, nullNHnullCnullOnull, nullCnullOnullNHnull; and wherein Q, p, N and X may independently be an integer from 1 to 10, or if Q is 1 A may be a (C1-C10)-alkyl chain, (C1-C10)-alkenyl chain or (C1-C10)-alkynyl chain which can optionally be interrupted 1 to 3 times by nullOnull or nullSnull or nullNnull; or a pharmaceutically acceptable salt or ester thereof, which compound is present in a concentration effective to inhibit growth of the bacterium. A may be an (C1-C10)-alkylene chain, (C1-C10)-alkyl chain, or (C1-C10)-alkynyl chain which is branched or unbranched, substituted or unsubstituted and can optionally be interrupted 1 to 3 times by nullOnull or nullSnull or nullNnull.
摘要翻译：本发明提供了一种抑制细菌生长的方法，其基本上使细菌与具有以下结构的化合物接触：其中R 1，R 2，R 3，R 4，R 5和R 6各自独立地为H，F，Cl， Br，I，-OH，-OR7，-CN，-COR7，-SR7，-N（R7）2，-NR7COR8，-NO2， - （CH2）pOR7， - （CH2）pX（R7）2， - （ CH2）pXR7COR8，直链或支链的取代或未取代的C1-C10烷基，C2-C10烯基，C2-C10炔基，C3-C10环烷基，C3-C10环烯基，硫代烷基，亚甲基硫代烷基，酰基，苯基，取代的苯基，或杂芳基; 其中与苯环的连接可以是-N，-S-，-O-或-C-; 其中R 7或R 8可以独立地是H，F，Cl，Br，I，-OH，-CN，-COH，-SH 2，-NH 2，-NHCOOH， - （CH 2）p OH， - （CH 2）p X（CH 2） - （CH 2）pXCOH，直链或支链的取代或未取代的C 1 -C 10烷基，硫代烷基，亚甲硫基烷基，酰基，苯基，取代的苯基或杂芳基; 其中A可以是-N 2 - ， - NH - ， - C = C = CH 2 - ， - C = C-C 2 HOH - ， - C = C-CH 2 - ， - CH 2 -CH 2 -O - ， - CH 2 -CH 2 -CH -O - ， - S - ， - S（= O）2 - ， - C = O-，

9. 发明申请

US20020192731A1 Method and composition for sterilizing surgical instruments 审中-公开
标题翻译：消毒手术器械的方法和组成
公开(公告)号：US20020192731A1
公开(公告)日：2002-12-19
申请号：US10007613
申请日：2001-10-26
发明人： Jason C. H. Shih
IPC分类号： G01N033/53 , G01N033/537 , G01N033/543 , C11D001/00 , G01N033/569 , C12Q001/02 , C12Q001/22 , C12Q001/18 , C12Q001/04 , C12N015/09 , C07F001/00 , C07K001/00 , C07H001/00 , C07J001/00 , C07C001/00 , C07D201/00
CPC分类号： A61L2/0023 , A61L2/0082 , A61L2/04 , A61L2/16
摘要： A method and composition for sterilizing articles that are contaminated with infectious prion protein, such as surgical instruments, kitchen utensils, laboratory tools, etc., comprising the steps of: (a) heating the articles to be treated at a moderate temperature well below the incineration temperature of said infectious prion protein, wherein said moderate temperature is sufficient to enhance the proteolytic susceptibility of infective prion protein associated with said articles; and (b) exposing the heated articles to a proteolytic enzyme that is effective for at least partial reduction of the infective protein prion associated with said articles under said moderate temperature.
摘要翻译：用于对被感染性朊病毒蛋白污染的制品进行灭菌的方法和组合物，例如手术器械，厨房用具，实验室工具等，其包括以下步骤：（a）在远低于所述感染性朊病毒蛋白的焚烧温度，其中所述中等温度足以增强与所述制品相关的感染性朊蛋白的蛋白水解易感性; 和（b）将加热的物品暴露于在所述中等温度下有效用于至少部分还原与所述制品相关的感染性蛋白质朊病毒的蛋白水解酶。

10. 发明申请

US20020044963A1 Cyclic AMP-specific phosphodiesterase inhibitors 失效
公开(公告)号：US20020044963A1
公开(公告)日：2002-04-18
申请号：US09737987
申请日：2000-12-15
发明人： John J. Gaudino
IPC分类号： C07D413/00 , C07D201/00 , C07D235/04 , C07D231/56 , A61K009/20
CPC分类号： C07D403/04
摘要： Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式